Investigating how CASP-11 affects lung problems and immune response after SARS-CoV-2 infection
Role of CASP-11 in SARS-CoV-2-induced lung pathologies and long-term immune protection
This study is looking at how a specific protein called CASP-11 affects lung damage and immune responses in people with COVID-19, especially to help understand why some vaccines might not last long against new variants and how they could lead to ongoing health problems; the goal is to find better ways to treat and support patients during and after their illness.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project ID | NIH-11072973 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of CASP-11 in the lung damage and immune responses associated with SARS-CoV-2 infections. It aims to explore how current vaccines may not provide long-lasting protection against emerging variants and how they can lead to long-term health issues, known as Post-Acute COVID Syndrome (PACS). By studying the inflammatory responses and cytokine release in COVID-19 patients, the research seeks to identify new therapeutic strategies to improve patient outcomes and manage acute infections more effectively.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals who have experienced COVID-19, particularly those with ongoing symptoms or complications.
Not a fit: Patients who have not been infected with SARS-CoV-2 or those who do not exhibit any symptoms related to COVID-19 may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatments and vaccines that provide better protection against COVID-19 and its long-term effects.
How similar studies have performed: Previous research has shown that understanding immune responses in viral infections can lead to significant advancements in treatment, indicating potential success for this approach.
Where this research is happening
Columbus, UNITED STATES
- Ohio State University — Columbus, United States (Active)
Researchers
- Principal investigator: Boyaka, Prosper N — Ohio State University
- Study coordinator: Boyaka, Prosper N
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.